Erratum: A new recombinant adeno-associated virus (AAV)-based random peptide display library system: Infection-defective AAV1.9-3 as a novel detargeted platform for vector evolution (Gene Therapy and Regulation (2010) 5 (31-55) DOI: 10.1142/S1568558610000197);A new recombinant adeno-associated virus (AAV)-based random peptide display library system: Infection-defective AAV1.9-3 as a novel detargeted platform for vector evolution

Gene Therapy and Regulation

Volumn 5, Issue 1, 2010, Pages 31-55

  Adachi, Kei ^a   Nakai, Hiroyuki ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Adeno associated virus; capsid engineering; directed evolution; gene therapy; random peptide display

Indexed keywords

AMINO ACID; HEPARIN; PARVOVIRUS VECTOR; PARVOVIRUS VECTOR 1.9 3; PEPTIDE; UNCLASSIFIED DRUG;

CELL STRAIN HEK293; CONFERENCE PAPER; GENE TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; INFECTION; MOUSE; NONHUMAN; SKIN FIBROBLAST; VIRUS CAPSID;

ADENO-ASSOCIATED VIRUS; MIRIDAE; MUS;

EID: 78149421208     PISSN: 13889532     EISSN: 15685586     Source Type: Journal    
DOI: 10.1142/S156855861100026X     Document Type: Erratum

References (63)

1. Arbetman, A. E., Lochrie, M., Zhou, S., Wellman, J., Scallan, C. et al. (2005). Novel caprine adeno-associated virus (AAV) capsid (AAV-Go.1) is closely related to the primate AAV-5 and has unique tropism and neutralization properties. J Virol, 79: 15238-15245.
2. Bartlett, J. S., Wilcher, R. and Samulski, R. J. (2000). Infectious entry pathway of adenoassociated virus and adeno-associated virus vectors. J Virol, 74: 2777-2785.
3. Boucas, J., Lux, K., Huber, A., Schievenbusch, S., Von Freyend, M. J. et al. (2009). Engineering adeno-associated virus serotype 2-based targeting vectors using a new insertion site-position 453-and single point mutations. J Gene Med, 11: 1103-1113.
4. Burton, M., Nakai, H., Colosi, P., Cunningham, J., Mitchell, R. et al. (1999). Coexpression of factor VIII heavy and light chain adeno-associated viral vectors produces biologically active protein. Proc Natl Acad Sci USA, 96: 12725-12730.
5. Ding, W., Zhang, L., Yan, Z. and Engelhardt, J. F. (2005). Intracellular trafficking of adeno-associated viral vectors. Gene Ther, 12: 873-880.
6. Duan, D., Sharma, P., Yang, J., Yue, Y., Dudus, L. et al. (1998). Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue. J Virol, 72: 8568-8577.
7. Excoffon, K. J., Koerber, J. T., Dickey, D. D., Murtha, M., Keshavjee, S. et al. (2009). Directed evolution of adeno-associated virus to an infectious respiratory virus. Proc Natl Acad Sci USA, 106: 3865-3870.
8. Foust, K. D., Nurre, E., Montgomery, C. L., Hernandez, A., Chan, C. M. et al. (2009). Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol, 27: 59-65.
9. Gao, G., Vandenberghe, L. H., Alvira, M. R., Lu, Y., Calcedo, R. et al. (2004). Clades of Adeno-associated viruses are widely disseminated in human tissues. J Virol, 78: 6381-6388.
10. Gao, G. P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J. et al. (2002). Novel adenoassociated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci USA, 99: 11854-11859.
11. Ghosh, A., Yue, Y., Long, C., Bostick, B. and Duan, D. (2007). Efficient wholebody transduction with trans-splicing adeno-associated viral vectors. Mol Ther, 15: 750-755.
12. Girod, A., Ried, M., Wobus, C., Lahm, H., Leike, K. et al. (1999). Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2. Nat Med, 5: 1052-1056.
13. Girod, A., Wobus, C. E., Zadori, Z., Ried, M., Leike, K. et al. (2002). The VP1 capsid protein of adeno-associated virus type 2 is carrying a phospholipase A2 domain required for virus infectivity. J Gen Virol, 83: 973-978.
14. Grimm, D., Lee, J. S., Wang, L., Desai, T., Akache, B. et al. (2008). In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adenoassociated viruses. J Virol, 82: 5887-5911.
15. Grimm, D., Zhou, S., Nakai, H., Thomas, C. E., Storm, T. A. et al. (2003). Preclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy. Blood, 102: 2412-2419.
16. Inagaki, K., Fuess, S., Storm, T. A., Gibson, G. A., Mctiernan, C. F. et al. (2006). Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8. Mol Ther, 14: 45-53.
17. Kern, A., Schmidt, K., Leder, C., Muller, O. J., Wobus, C. E. et al. (2003). Identification of a heparin-binding motif on adeno-associated virus type 2 capsids. J Virol, 77: 11072-11081.
18. Koerber, J. T., Klimczak, R., Jang, J. H., Dalkara, D., Flannery, J. G. et al. (2009). Molecular evolution of adeno-associated virus for enhanced glial gene delivery. Mol Ther, 17: 2088-2095.
19. Koivunen, E.,Wang, B. and Ruoslahti, E. (1995). Phage libraries displaying cyclic peptides with different ring sizes: ligand specificities of the RGD-directed integrins. Biotechnology (NY), 13: 265-270.
20. Li, W., Asokan, A., Wu, Z., Van Dyke, T., Diprimio, N. et al. (2008). Engineering and selection of shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles. Mol Ther, 16: 1252-1260.
21. Li, W., Zhang, L., Johnson, J. S., Zhijian, W., Grieger, J. C. et al. (2009). Generation of Novel AAV Variants by Directed Evolution for Improved CFTR Delivery to Human Ciliated Airway Epithelium. Mol Ther, 17: 2067-2077.
22. Lochrie,M.A., Tatsuno, G. P., Arbetman, A. E., Jones,K., Pater, C. et al. (2006a). Adenoassociated virus (AAV) capsid genes isolated from rat and mouse liver genomic DNA define two new AAV species distantly related to AAV-5. Virology, 353: 68-82.
23. Lochrie, M. A., Tatsuno, G. P., Christie, B., Mcdonnell, J. W., Zhou, S. et al. (2006b). Mutations on the external surfaces of adeno-associated virus type 2 capsids that affect transduction and neutralization. J Virol, 80: 821-834.
24. Loiler, S. A., Conlon, T. J., Song, S., Tang, Q., Warrington, K. H. et al. (2003). Targeting recombinant adeno-associated virus vectors to enhance gene transfer to pancreatic islets and liver. Gene Ther, 10: 1551-1558.
25. Maguire, C. A., Gianni, D., Meijer, D. H., Shaket, L. A., Wakimoto, H. et al. (2009). Directed evolution of adeno-associated virus for glioma cell transduction. J Neurooncol, 96: 337-347.
26. Maersch, S., Huber, A., Buning, H., Hallek, M. and Perabo, L. (2010). Optimization of stealth adeno-associated virus vectors by randomization of immunogenic epitopes. Virology, 397: 167-175.
27. Maheshri, N., Koerber, J. T., Kaspar, B. K. and Schaffer, D. V. (2006). Directed evolution of adeno-associated virus yields enhanced gene delivery vectors. Nat Biotechnol, 24: 198-204.
28. Michelfelder, S., Kohlschutter, J., Skorupa, A., Pfennings, S., Muller, O. et al. (2009). Successful expansion but not complete restriction of tropism of adeno-associated virus by in vivo biopanning of random virus display Peptide libraries. PLoS One, 4: e5122.
29. Michelfelder, S., Lee, M. K., Delima-Hahn, E., Wilmes, T., Kaul, F. et al. (2007). Vectors selected from adeno-associated viral display peptide libraries for leukemia cell-targeted cytotoxic gene therapy. Exp Hematol, 35: 1766-1776.
30. Mori, S.,Wang, L., Takeuchi, T. and Kanda, T. (2004). Two novel adeno-associated viruses from cynomolgus monkey: pseudotyping characterization of capsid protein. Virology, 330: 375-383.
31. Muller, O. J., Kaul, F., Weitzman, M. D., Pasqualini, R., Arap, W. et al. (2003). Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors. Nat Biotechnol, 21: 1040-1046.
32. Muller, O. J., Leuchs, B., Pleger, S. T., Grimm, D., Franz, W. M. et al. (2006). Improved cardiac gene transfer by transcriptional and transductional targeting of adeno-associated viral vectors. Cardiovasc Res, 70: 70-78.
33. Nakai, H., Storm, T. A. and Kay, M. A. (2000a). Increasing the size of rAAV-mediated expression cassettes in vivo by intermolecular joining of two complementary vectors. Nat Biotechnol, 18: 527-532.
34. Nakai, H., Storm, T. A. and Kay, M. A. (2000b). Recruitment of single-stranded recombinant adeno-associated virus vector genomes and intermolecular recombination are responsible for stable transduction of liver in vivo. J Virol, 74: 9451-9463.
35. Nakai, H., Wu,X., Fuess, S., Storm, T. A.,Munroe, D. et al. (2005). Large-scale molecular characterization of adeno-associated virus vector integration in mouse liver. J Virol, 79: 3606-3614.
36. Opie, S. R., Warrington, K. H., Jr., Agbandje-Mckenna, M., Zolotukhin, S. and Muzyczka, N. (2003). Identification of amino acid residues in the capsid proteins of adenoassociated virus type 2 that contribute to heparan sulfate proteoglycan binding. J Virol, 77: 6995-7006.
37. Pacak, C. A., Mah, C. S., Thattaliyath, B. D., Conlon, T. J., Lewis, M. A. et al. (2006). Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo. Circ Res, 99: e3-9.
38. Penaud-Budloo, M., Le Guiner, C., Nowrouzi, A., Toromanoff, A., Cherel, Y. et al. (2008). Adeno-associated virus vector genomes persist as episomal chromatin in primate muscle. J Virol, 82: 7875-7885.
39. Perabo, L., Buning, H.,Kofler, D.M., Ried,M. U., Girod, A. et al. (2003). In vitro selection of viral vectors with modified tropism: the adeno-associated virus display. Mol Ther, 8: 151-157.
40. Perabo, L., Endell, J., King, S., Lux, K., Goldnau, D. et al. (2006a). Combinatorial engineering of a gene therapy vector: directed evolution of adeno-associated virus. J Gene Med, 8: 155-162.
41. Perabo, L., Goldnau, D., White, K., Endell, J., Boucas, J. et al. (2006b). Heparan sulfate proteoglycan binding properties of adeno-associated virus retargeting mutants and consequences for their in vivo tropism. J Virol, 80: 7265-7269.
42. Rabinowitz, J. E., Bowles, D. E., Faust, S. M., Ledford, J. G., Cunningham, S. E. et al. (2004). Cross-dressing the virion: the transcapsidation of adeno-associated virus serotypes functionally defines subgroups. J Virol, 78: 4421-4432.
43. Rabinowitz, J. E., Xiao, W. and Samulski, R. J. (1999). Insertional mutagenesis of AAV2 capsid and the production of recombinant virus. Virology, 265: 274-285.
44. Sarkar, R., Mucci, M., Addya, S., Tetreault, R., Bellinger, D. A. et al. (2006). Long-term efficacy of adeno-associated virus serotypes 8 and 9 in hemophilia a dogs and mice. Hum Gene Ther, 17: 427-439.
45. Schmidt, M., Katano, H., Bossis, I. and Chiorini, J. A. (2004). Cloning and characterization of a bovine adeno-associated virus. J Virol, 78: 6509-6516.
46. Sellner, L., Stiefelhagen, M., Kleinschmidt, J. A., Laufs, S., Wenz, F. et al. (2008). Generation of efficient human blood progenitor-targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells. Exp Hematol, 36: 957-964.
47. Shen, X., Storm, T. and Kay, M. A. (2007). Characterization of the relationship of AAV capsid domain swapping to liver transduction efficiency. Mol Ther, 15: 1955-1962.
48. Shi, W., Arnold, G. S. and Bartlett, J. S. (2001). Insertional mutagenesis of the adenoassociated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors targeted to alternative cell-surface receptors. Hum Gene Ther, 12: 1697-1711.
49. Shi, W. and Bartlett, J. S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol Ther, 7: 515-525.
50. Shi, X., Fang, G., Shi, W. and Bartlett, J. S. (2006). Insertional mutagenesis at positions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum Gene Ther, 17: 353-361.
51. Stiefelhagen, M., Sellner, L., Kleinschmidt, J. A., Jauch, A., Laufs, S. et al. (2008). Application of a haematopoetic progenitor cell-targeted adeno-associated viral (AAV) vector established by selection of an AAV random peptide library on a leukaemia cell line. Genet Vaccines Ther, 6: 12.
52. Summerford, C., Bartlett, J. S. and Samulski, R. J. (1999). AlphaVbeta5 integrin: a coreceptor for adeno-associated virus type 2 infection. Nat Med, 5: 78-82.
53. Summerford, C. and Samulski, R. J. (1998). Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol, 72: 1438-1445.
54. Thomas, C. E., Storm, T. A., Huang, Z. and Kay, M. A. (2004). Rapid uncoating of vector genomes is the key to efficient liver transduction with pseudotyped adeno-associated virus vectors. J Virol, 78: 3110-3122.
55. Vandendriessche, T., Thorrez, L., Acosta-Sanchez, A., Petrus, I., Wang, L. et al. (2007). Efficacy and safety of adeno-associated viral vectors based on serotype 8 and 9 vs. lentiviral vectors for hemophilia B gene therapy. J Thromb Haemost 5: 16-24.
56. Wang, Z., Zhu, T., Qiao, C., Zhou, L., Wang, B. et al. (2005). Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Nat Biotechnol, 23: 321-328.
57. Warrington, K. H., Jr., Gorbatyuk, O. S., Harrison, J. K., Opie, S. R., Zolotukhin, S. et al. (2004). Adeno-associated virus type 2 VP2 capsid protein is nonessential and can tolerate large peptide insertions at its N terminus. J Virol, 78: 6595-6609.
58. Waterkamp, D. A., Muller, O. J., Ying, Y., Trepel, M. and Kleinschmidt, J. A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J Gene Med, 8: 1307-1319.
59. Wobus, C. E., Hugle-Dorr, B., Girod, A., Petersen, G., Hallek, M. et al. (2000). Monoclonal antibodies against the adeno-associated virus type 2 (AAV-2) capsid: epitope mapping and identification of capsid domains involved in AAV-2-cell interaction and neutralization of AAV-2 infection. J Virol, 74: 9281-9293.
60. Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-Mckenna, M. et al. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J Virol, 74: 8635-8647.
61. Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T. et al. (2002). The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc Natl Acad Sci USA, 99: 10405-10410.
62. Yang, L., Jiang, J., Drouin, L. M., Agbandje-Mckenna, M., Chen, C. et al. (2009). A myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selection. Proc Natl Acad Sci USA, 106: 3946-3951.
63. Ying, Y., Muller, O. J., Goehringer, C., Leuchs, B., Trepel, M. et al. (2010). Heart-targeted adeno-associated viral vectors selected by in vivo biopanning of a random viral display peptide library. Gene Ther, 17: 980-990.